ethyl 5-bromo-4-oxopentanoate | 14594-25-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 5-bromo-4-oxopentanoate
• CAS: 14594-25-3
• 化学式: C₇H₁₁BrO₃
• 分子量: 223.067
• InChiKey: HZTCCISWRZQSRU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 5-bromo-4-oxopentanoate 在 硫酸 、 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 ethyl 3-(6-{2-[6-(methylamino)-2-pyridyl]ethoxy}benzo[b]furan-3-yl)propanoate
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Novel Potent and Selective α_vβ₃/α_vβ₅ Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core

  摘要：

  A novel series of potent and selective alpha(v)beta(3)/alpha(v)beta(5) dual inhibitors was designed, synthesized, and evaluated against several integrins. These compounds were synthesized through a Mitsunobu reaction between the guanidinium mimetics and the corresponding central templates. Guanidinium mimetics with enhaced rigidity (i.e., (2-pyridylamino)propoxy versus the 2-(6-methylamino-2-pyridyl)ethoxy) led to improved activity toward alpha(v)beta(3). Exemplary oral bioavailability in mice was achieved using the indole central scaffold. Although, oral bioavailability was maintained when the indole molecular core was replace with the bioisosteric benzofuran or benzothiophene ring systems, it was found to not significantly impact the integrin activity or selectivity. However, the indole series displayed the best in vivo pharmacokinetic properties. Thus, the indole series was selected for further structure-activity relationships to obtain more potent alpha(v)beta(3)/alpha(v)beta(5) dual antagonist with improved oral bioavailability.

  DOI：

  10.1021/jm049725u
• 作为产物：
  描述：

  4-戊烯酸乙酯 生成 ethyl 5-bromo-4-oxopentanoate
  参考文献：
  名称：

  Rykowski,Z. et al., Roczniki Chemii, 1977, vol. 51, p. 1675 - 1678

  摘要：

  DOI：

文献信息

• Sulfonamide peri-substituted bicyclics for occlusive artery disease
  申请人：Singh Jasbir

  公开号：US20060079520A1

  公开（公告）日：2006-04-13

  Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  酰基磺酰胺，带有周取代的融合双环环化合物，用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是：
• [EN] BIS-(ARYL/HETEROARYL)-METHYLENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND THEIR USE FOR TREATING CANCER<br/>[FR] COMPOSÉS DE BIS(ARYL/HÉTÉROARYL)MÉTHYLÈNE, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：UNIV MCGILL

  公开号：WO2013091082A1

  公开（公告）日：2013-06-27

  The present disclosure relates to novel bis-(aryl/heteroaryl)-methylene compounds of formula (I) having vitamin D receptor agonist and histone deacetylase (HDAC) inhibitory efficacy as well as to methods for reducing or inhibiting the proliferation of cancer cells or for treating cancer cells.

  本公开涉及具有维生素D受体激动剂和组蛋白去乙酰化酶（HDAC）抑制活性的新型双（芳基/杂芳基）亚甲基化合物（I）的公式，以及用于减少或抑制癌细胞增殖或治疗癌细胞的方法。
• Identification and isolation of lantibiotics from culture: a bioorthogonal chemistry approach
  作者：Jing Li、Genevieve Girard、Bogdan I. Florea、Paul P. Geurink、Nan Li、Gijsbert A. van der Marel、Mark Overhand、Herman S. Overkleeft、Gilles P. van Wezel

  DOI：10.1039/c2ob26050f

  日期：——

  A distinguishing feature of the lantibiotic family of cyclic peptides is the presence of thioethers. Treatment of a lantibiotic with an alkaline solution at high pH gives rise to a β-elimination reaction yielding the corresponding ring opened precursor, containing a dehydro-amino acid residue. We here reveal in a proof-of-concept study that a ring opened lantibiotic (mersacidin) can be captured for pull-down from a culture broth, subsequently released and identified by mass spectrometry.

  羊蛋白质家族的一个显著特征是存在硫醚。在碱性溶液中，在较高pH值下处理羊蛋白质会发生β-消除反应，产生相应的环开裂前体，包含一个脱氢氨基酸残基。在此，我们在概念验证研究中揭示了环开裂的羊蛋白质（mersacidin）可以从培养液中被捕获并拉下来，随后通过质谱法释放和鉴定。
• Synthesis of 5-aminolevulinic acid with nontoxic regents and renewable methyl levulinate
  作者：Yuxia Zai、Yunchao Feng、Xianhai Zeng、Xing Tang、Yong Sun、Lu Lin

  DOI：10.1039/c9ra01517e

  日期：——

  Synthesis of 5-aminolevulinic acid (5-ALA) was presented with novel bromination of biobased methyl levulinate (ML), followed by ammoniation and hydrolysis. Copper bromide (CuBr2) was employed as the bromination reagent with higher selectivity and activity instead of the conventional liquid bromine (Br2). 5-ALA was obtained in a high yield (64%) and purity (>95%) by optimum design, which is of great

  5-氨基乙酰丙酸 (5-ALA) 的合成提出了生物基乙酰丙酸甲酯 (ML) 的新型溴化，然后氨化和水解。采用溴化铜（CuBr 2）代替传统的液溴（Br 2）作为溴化试剂，具有更高的选择性和活性。5-ALA通过优化设计获得了高收率（64%）和纯度（>95%）的5-ALA，具有很大的产业化潜力。
• Substituted 3-Amino-Pyrrolidino-4-Lactams
  申请人：Piotrowski David W.

  公开号：US20070299076A1

  公开（公告）日：2007-12-27

  The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R 1 , n and R 2 are as described herein; compositions thereof; and uses thereof.

  这项发明提供了式（1）的化合物，以及其药用可接受的盐，其中R1、n和R2如本文所述；以及它们的组合物；以及它们的用途。